MGAT3 and early-onset autosomal dominant Alzheimer disease: Preliminary data illustrate MGAT3 mRNA as a potential biomarker of response to vitamin D therapy in Alzheimer’s disease, hinting at its translational potential; however, these findings remain to be independently validated [9].